About
ALP Bio AG uses human tonsil organoid technology combined with protein AI models to predict, assess, and reduce the immunogenicity risk of therapeutic antibodies before clinical development.
Explore ALP Bio AG's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.